Companies to follow in 2024: hVIVO

Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas and mining small caps.

hVIVO

hVIVO, a biotech small cap specialising in vaccine and antiviral testing using ‘human challenge’ clinical trials, leapt ahead this year, its value increasing by more than 60pc as it recorded higher revenue and a bulging order book.

One of the biotech small caps brought to market by Cathal Friel, alongside Poolbeg Pharma (see below) and Amryt Pharma, HVO made headlines through the first months of the pandemic, working with the vaccines task force to organise the UK’s first Covid human challenge trial, in which volunteers were inoculated under controlled conditions with the virus to test its impact on the immunity system. The trial helped HVO develop an infection challenge model able to serve as a ‘plug and play’ platform for testing new Covid variants.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO to hold AGM on 13 May 2024

    hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report and Accounts for the year ended

    hVIVO plc

    Hvivo reports 44% Rise in earnings and Record Year in 2023

    Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation and amortisation (Ebitda) increased to £13m

    hVIVO plc

    hVIVO Investor Conference

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,